EGFR and non-small cell lung carcinoma: Later, Goss et al., reported no benefit in terms of DFS (HR = 1.28, 95% CI 0.92–1.76, p = 0.14) or OS (HR = 1.24, 95% CI 0.90–1.71, p = 0.18) of 1-year adjuvant gefitinib in resected NSCLC (stage IB-IIIA) not selected for EGFR activating mutations [41].